Exenatide Implant not checked
Vivani Medical, Inc · NPM115/NPM119
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Exenatide Implant is a drug:device combination that delivers steady levels of exenatide, a glucagon-like peptide-1(GLP-1) receptor agonist, for an extended period of time following subdermal insertion.”In the company’s words, NCT05670379 on ClinicalTrials.gov
- Tested for
- Overweight and Obesity, Type2diabetes
- Main trialPhase 1
- “The purpose of this study is to evaluate the safety, tolerability and drug levels of an exenatide implant administered subcutaneously.”In the company’s words, NCT05670379 on ClinicalTrials.gov
- Other names
- NPM115/NPM119
- Copy of
- Bydureon Bcise (Astrazeneca AB)Tested side by side with the original in NCT05670379
Other drugs for Overweight and Obesity
- RetatrutideEli Lilly · Phase 3
- TradipitantVanda Pharmaceuticals · Phase 3
- LiraglutideNovo Nordisk · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- HRS-7535Hengrui · Kailera · Phase 3
- IN-B00009HK inno.N · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 21 Aug 2025 | Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026